Biohaven to Present on Migraine Phase 3 at American Academy Of Neurology

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that results from the pivotal rimegepant Zydis® ODT Phase 3 clinical trial will be presented as a late-breaking oral presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, May 4-10, 2019. This presentation is 1 of only 11 abstracts accepted as part of the Emerging Science (Late-Breaking) program, and the only CGRP-targeting migraine data accepted for the Late-Breaking session. Rimegepant is an oral, single-dose, selective and potent small molecule calcitonin gene-related peptide (CGRP) receptor antagonist in development for the acute treatment of migraine.

AAN Emerging Science (Late-Breaking) Presentation Details:

Data Blitz Oral and Poster Presentation Title: Efficacy, Safety, and Tolerability of Rimegepant 75 mg Orally Dissolving Tablet for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial, Study 303 (Data Blitz #005, Poster #075)

Presentation Date: May 7, 2019
Presentation Time: Oral at 11:57 a.m.; Poster displayed 11:30 a.m.-6:30 p.m.

Company Off-Site CGRP Presentation and Migraine Expert Panel, at 7:00 p.m. ETon May 7, 2019:
Richard Lipton, MD
Albert Einstein College of Medicine / Montefiore Headache Center

David Kudrow, MD
California Medical Clinic for Headache

Jelena Pavlovic, MD, PhD
Albert Einstein College of Medicine / Montefiore Headache Center

Moderated by: 
Kishen Mehta

https://www.biospace.com/article/releases/biohaven-announces-late-breaking-oral-presentation-of-rimegepant-zydis-odt-phase-3-results-at-american-academy-of-neurology-aan-2019-annual-meeting-and-new-data-release-at-investor-event/